ISSN print edition: 0366-6352
ISSN electronic edition: 1336-9075
Registr. No.: MK SR 9/7

Published monthly
 

In silico insights into pyrazolochalcones: molecular modeling and design of novel antagonists of estrogen receptor for breast cancer intervention using QSAR modeling, molecular docking, molecular dynamics, DFT, and ADMET studies

Philip John Ameji, Amneh Shtaiwi, and Rohana Adnan

School of Chemical Sciences, Universiti Sains Malaysia (USM), Gelugor, Malaysia

 

E-mail: ameji.john@fulokoja.edu.ng

Received: 2 March 2026  Accepted: 4 June 2026

Abstract:

Estrogen receptor alpha (ERα) is the key mediator of estrogen receptor-positive (ER+) breast carcinoma; the most common form of breast malignancy and the principal target of existing medications against the disease. Due to the declining efficacy of the existing drugs against ER+ breast cancer, it has become expedient to search for newer and better options. Herein, we applied integrated in silico drug discovery techniques, including 2D-QSAR modeling, molecular docking, MM/GBSA calculations, ADMET profiling, molecular dynamics, and DFT calculations to prioritize pyrazolochalcone-based ERα antagonists. The optimal QSAR model achieved R2train = 0.946, R2adj = 0.934, Q2 = 0.917, and cRp2 = 0.888. In addition, the model displays sound external predictive ability (R2Test = 0.725, k = 1.024, k’ = 0.974, and CCC = 0.73). Among the designed ligands, PC-2 demonstrated the most promising characteristics to be prioritized as a lead molecule in the search for potent and less toxic antagonists of ERα for breast cancer intervention. The ligand showed the strongest binding interactions with the receptor (∆G = − 8.8 kcal/mol and ∆GT = − 55.04 kcal/mol), good gastrointestinal absorption (GIA) potential (≈ 70%), negative AMES status, and a non-inhibitor of hERG1. Also, 100 ns MD simulations confirmed a stable binding pose. While the findings of this in silico study highlights PC-2 as a priority candidate for synthesis and experimental evaluation, confirmation of its potential advantages over tamoxifen will require further in vitro and in vivo validation.

Keywords: Pyrazolochalcones; QSAR; ERα; MM/GBSA; Breast cancer; Tamoxifen

Full paper is available at www.springerlink.com.

DOI: 10.1007/s11696-026-05174-w

 

Chemical Papers 80 (11) 13237–13256 (2026)

Friday, November 20, 2026

IMPACT FACTOR 2025
2.7
SCImago Journal Rank 2025
0.41
SEARCH
Advanced
VOLUMES
© 2026 Chemical Papers